BioSpace News Archive

SamanTree Medical SA Announces Exciting Clinical Data Showing the Potential of the Histolog ® Scanner to Be a Valid Alternative to Frozen Section Analysis in Prostate Cancer.

IASO Biotherapeutics announced that the Investigational New Drug application for its in-house developed BCMA CAR-T CT103A has been approved by the U.S. Food and Drug Administration for use in U.S. clinical trials for relapsed/refractory multiple myeloma.

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that the FDA has granted a new Biosimilar User Fee Amendment goal date of April 13, 2023, for Alvotech’s original Biologics License Application for AVT02 as biosimilar to Humira®.

Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines.

Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has completed the planned enrollment of subjects in the global, randomized, double-blind Phase 3 clinical trial of its investigational respiratory syncytial virus (RSV) vaccine candidate, MVA-BN ® RSV in adults ≥60 years of age.

BioNTech SE and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that the companies provided approximately 11,500 doses of mRNA-based COVID-19 vaccines which arrived on the Chinese Mainland on December 21, 2022.

ProKidney Corp. today announced that Dr. Tim Bertram, Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare Conference in San Francisco on Wednesday, January 11th, 2023, at 3:45 PM PT.

Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and collaboration agreement focused on the discovery, development and commercialization of new genetic medicines.

NanoString Technologies, Inc. today announced that the company’s management is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference.

Rocket Pharmaceuticals, Inc. today announces updates from the Company’s end-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) regarding RP-A501, the Company’s investigational adeno-associated virus (AAV)-based gene therapy for Danon Disease.